WHO ICTRP trial
A prospective, small sample and observational study of TACE combined with portal…
ChiCTR2200059078 · Chinese Clinical Trial Registry (ChiCTR) · Not Recruiting
Key facts
| Trial ID | ChiCTR2200059078 |
|---|---|
| Public title | A prospective, small sample and observational study of TACE combined with portal vein tumor thrombus seed implantation and Lenvatinib in the treatment of HCC with portal vein tumor thrombus |
| Scientific title | A prospective, small sample and observational study of TACE combined with portal vein tumor thrombus seed implantation and Lenvatinib in the treatment of HCC with portal vein tumor thrombus |
| Primary sponsor | Henan Cancer Hospital |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Not Recruiting |
| Study type | Observational study |
| Phase | 4 |
| Countries | China |
| Conditions | Hepatocellular Carcinoma with Portal Vein Canc |
| Interventions | case series:TACE combined with particle implantation combined with Lenvatinib |
| Registration date | Apr 24, 2022 |
| Target size | case series:30 |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: